Side-by-side · Research reference

FOXO4-DRIvsPTD-DBM

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED12/45 cited

BAnimal-StrongHUMAN-REVIEWED10/40 cited

FOXO4-DRI

Senolytic Peptide · D-Retro-Inverso

p53-TADMolecular targetBourgeois 2025

Pre-clinicalDevelopment stage

SQRoute (animal)

SQ · Animal models only

PTD-DBM

Wnt Pathway Activator · Fusion Peptide

Topical / SQAdministrationLee 2023 Ryu 2023

Animal-onlyEvidence level

Wnt/β-cateninPrimary pathway

Topical / SQ · Study-dependent

01Mechanism of Action

Parameter

FOXO4-DRI

PTD-DBM

Primary target

FOXO4-p53 protein complex in senescent cellsBourgeois 2025 Tripathi 2021

CXXC5–Dishevelled protein-protein interaction

Pathway

FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells

Inhibit CXXC5 binding to Dishevelled → Release Wnt/β-catenin pathway inhibitionLee 2015 Ryu 2023

Downstream effect

Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021 Alameen 2026

Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation

Feedback intact?

—

Not applicable — pathway derepression rather than receptor agonism

Origin

D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance

Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5

Antibody development

—

02Dosage Protocols

Parameter

FOXO4-DRI

PTD-DBM

Animal dose (mouse)

5 mg/kg

SQ injection, aged mouse model (testosterone restoration).

—

Frequency (animal)

Variable — single or intermittent dosing

Protocol-dependent; no standardised regimen.

—

Human equivalent (theoretical)

~0.4 mg/kg (28 mg / 70 kg adult)

Extrapolated using allometric scaling; no clinical validation.

—

Evidence basis

Animal / mechanistic

Animal models only (mice)

Route

SQ (animal)

No human route established.

—

Duration

Weeks to months (animal studies)

Senescent cell clearance observed within weeks.

—

Clinical status

No human trials completed

—

Wound healing protocol

—

Hydrogel patch delivery (concentration not disclosed)

Pyrogallol-HA patch, murine model.

Hair regeneration protocol

—

Topical application (exact dose not disclosed)

Wound-induced hair neogenesis model, mice.

Co-administration

—

Valproic acid (GSK-3β inhibitor) for wound healing synergyLee 2023

Combined treatment maximized scar reduction.

Human translation

—

No published human studies

04Side Effects & Safety

Parameter

FOXO4-DRI

PTD-DBM

Pulmonary hypertension risk

Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023

—

Context-dependent toxicity

Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023

—

Off-target apoptosis

Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)

—

Immune perturbation

Senescent cells contribute to immune surveillance; clearance effects unknown

—

Human safety unknown

No clinical trials — toxicity profile in humans not established

—

Reported adverse events

—

None reported in animal studies

Wnt pathway activation risks

—

Theoretical risk of aberrant proliferation; Wnt dysregulation linked to tumorigenesis

Long-term safety

—

Unknown — no chronic dosing or human data

Delivery vehicle effects

—

HA-PG hydrogel well-tolerated in mice; human translation pending

Absolute Contraindications

FOXO4-DRI

·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
·Pregnancy / lactation (no safety data)

PTD-DBM

·Active malignancy (Wnt pathway involvement in tumorigenesis)
·Pregnancy / lactation (no safety data)

Relative Contraindications

FOXO4-DRI

·Active malignancy (senescence as tumour suppressor mechanism)
·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)

PTD-DBM

·History of Wnt-driven tumors
·Skin lesions with uncertain malignant potential

05Administration Protocol

Parameter

FOXO4-DRI

PTD-DBM

1. Pre-clinical route

Subcutaneous injection used in rodent models. No human administration protocol exists.

Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days.Lee 2023

2. Reconstitution (animal)

Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.

Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models.Ryu 2023

3. Dosing schedule

Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.

PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream.Lee 2023

4. Clinical development status

No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.

Not disclosed in available literature. Peptide stability and storage conditions not published.

5. Safety monitoring (proposed)

Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.

—